BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.
More information is coming soon.
Recent BDSI News
BioDelivery Sciences Reports First Quarter 2021 Results
May 6, 2021
Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery ...
BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021
April 20, 2021
RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021 ...
BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results
March 10, 2021
Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million , Full-Year EBITDA Margin of 26% and Operating Cash Generation of $25 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today ...